Editorial Material
Green & Sustainable Science & Technology
Sylvia Lorek
Summary: Sylvia Lorek argues that addressing sufficiency in a broader sense can address more than just the issue of increasing plastic waste.
NATURE SUSTAINABILITY
(2023)
Editorial Material
Anesthesiology
Elaine Cole, Nicola Curry, Ross Davenport
Summary: Emerging evidence suggests inequalities in healthcare provision between women and men, including in trauma care. While an anti-fibrinolytic drug showed similar effects in reducing trauma deaths for both sexes, real-world data indicates that females are less likely to receive this treatment compared to males. Further research is needed to examine the impact of age and injury mechanisms on the decision to treat.
BRITISH JOURNAL OF ANAESTHESIA
(2022)
Article
Oncology
Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra-Kalyani, Yajun Liu, Hong Zhao, Youwei Bi, Jiang Liu, Atiqur Rahman, Emily Wearne, Idara Ojofeitimi, Lauren Tesh Hotaki, Dianne Spillman, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Summary: The FDA has granted accelerated approval to sotorasib for the treatment of advanced non-small cell lung cancer with a KRAS G12C mutation. The drug has shown significant overall response rate and duration of response in clinical trials, with common adverse reactions including diarrhea and musculoskeletal pain.
CLINICAL CANCER RESEARCH
(2022)
Review
Pediatrics
Sigrid Hegna Ingvaldsen, Tora Sund Morken, Dordi Austeng, Olaf Dammann
Summary: This paper proposes the concept of visuopathy of prematurity (VOP) and suggests that visual abnormalities in premature infants go beyond just abnormal retinal vascularization, including visual processing abnormalities and changes in brain structure. Furthermore, it highlights the association between sustained systemic inflammation in premature infants and the risk of ROP and visual deficits.
PEDIATRIC RESEARCH
(2022)
Review
Virology
Matteo Centazzo, Lara Manganaro, Gualtiero Alvisi
Summary: Human immunodeficiency virus 1 (HIV-1) viral protease (PR) is not only involved in virion maturation but also has the ability to cleave host cell proteins. It targets proteins involved in translation, cell survival, and innate antiviral responses, thereby promoting viral production, immune evasion, and viral dissemination. However, there is still much to be discovered about the modulation of host cell function by HIV-1 PR.
Article
Biochemistry & Molecular Biology
Joris van de Haar, Xuhui Ma, Salo N. Ooft, Pim W. van der Helm, Louisa R. Hoes, Sara Mainardi, David J. Pinato, Kristi Sun, Lisa Salvatore, Giampaolo Tortora, Ina Valeria Zurlo, Silvana Leo, Riccardo Giampieri, Rossana Berardi, Fabio Gelsomino, Valeria Merz, Federica Mazzuca, Lorenzo Antonuzzo, Gerardo Rosati, Chara Stavraka, Paul Ross, Maria Grazia Rodriquenz, Michele Pavarana, Carlo Messina, Timothy Iveson, Federica Zoratto, Anne Thomas, Elisabetta Fenocchio, Margherita Ratti, Ilaria Depetris, Massimiliano Cergnul, Cristina Morelli, Michela Libertini, Alessandro Parisi, Michele De Tursi, Nicoletta Zanaletti, Ornella Garrone, Janet Graham, Raffaella Longarini, Stefania Maria Gobba, Angelica Petrillo, Emiliano Tamburini, Nicla La Verde, Fausto Petrelli, Vincenzo Ricci, Lodewyk F. A. Wessels, Michele Ghidini, Alessio Cortellini, Emile E. Voest, Nicola Valeri
Summary: Genomic analysis identified KRAS(G12) mutations as potential biomarkers of resistance to trifluridine/tipiracil treatment in metastatic colorectal cancer. Real-world data and phase 3 clinical trial data confirmed the significant association between KRAS(G12) mutations and reduced overall survival. These findings provide important implications for precision medicine in approximately 28% of patients with metastatic colorectal cancer.
Article
Oncology
Jingyuan Wang, Yi Xiao, Fotios Loupakis, Sebastian Stintzing, Yan Yang, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Tianshu Liu, Volker Heinemann, Alfredo Falcone, Lin Shen, Joshua Millstein, Heinz-Josef Lenz
Summary: This study found that genetic polymorphisms in the cGAS-STING pathway may predict the efficacy of cetuximab-based treatment in patients with metastatic colorectal cancer. This has important implications for the development of personalized treatment strategies.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Qunli Xiong, Zhu Zeng, Yang Yang, Ya Wang, Yongfeng Xu, Ying Zhou, Jinlu Liu, Zhiwei Zhang, Meng Qiu, Qing Zhu
Summary: We reported a case of a male patient with advanced rectal cancer who harbored a KRAS amplification during anti-EGFR treatment. The dynamic change of KRAS copy number on ctDNA appeared to strongly correlate with treatment response, suggesting it as a potential negative predictive biomarker. Additionally, RAS and BRAF wild-type mCRC patients who are resistant to first-line FOLFIRI plus cetuximab therapy may respond well to the FOLFIRI plus cetuximab rechallenged strategy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyurek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan Sayin
Summary: This retrospective study investigated the impact of KRAS mutational status on clinical outcome in patients with metastatic non-small cell lung cancer (NSCLC). The results showed that KRAS(MUT) patients had better response to immune checkpoint blockade (ICB) but worse response to platinum doublet chemotherapy (PT). Additionally, KRAS(WT) patients with high PD-L1 expressing tumors responded better to PT than ICB.
Article
Oncology
Said A. Khelwatty, Soozana Puvanenthiran, Sharadah Essapen, Izhar Bagwan, Alan M. Seddon, Helmout Modjtahedi
Summary: The study revealed that high levels of HER2 expression were found in CRC patients treated with cetuximab, which was associated with shorter progression free survival. The results support the emergence of HER2 as a therapeutic target in mCRC patients.
Article
Oncology
Hiroyuki Arai, Joshua Millstein, Fotios Loupakis, Sebastian Stintzing, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Shannon M. Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Heinz-Josef Lenz
Summary: The study found that certain polymorphisms in the PTF genes are significantly associated with progression-free survival in patients receiving cetuximab treatment, indicating their potential predictive value for colorectal cancer therapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T. J. van Bussel, Katia Fiorella Dotti, Elena Elez, Maria J. de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris
Summary: This study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF (V600E)-mutant metastatic colorectal cancer. The results showed a high incidence of adverse events and no evidence of improved anti-tumor activity, leading to study discontinuation.
Article
Oncology
Catherine G. Tran, Paolo Goffredo, Sarah L. Mott, Mohammed O. Suraju, Julia F. Kohn, Aditi Mishra, Jean-Nicolas Vauthey, Imran Hassan
Summary: This study investigates the impact of laterality, microsatellite instability (MSI), and KRAS status on conditional overall survival (COS) in colon cancer. The results show that mKRAS is associated with worse COS, suggesting a more aggressive biological behavior.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Environmental Sciences
Adriana A. Zuniga-Teran, Andrea K. Gerlak, Alison D. Elder, Alexander Tam
Summary: The issue of green infrastructure (GI) justice is receiving increasing attention, with research indicating that GI injustice stems from a history of unequal investment and non-participatory decision-making processes. Cities need to take action to address this issue.
ENVIRONMENTAL SCIENCE & POLICY
(2021)
